[{"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher C. Gibson Ph.D.", "age": 40, "title": "Co-Founder, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 806716, "exercisedValue": 2177540, "unexercisedValue": 222044}, {"maxAge": 1, "name": "Ms. Tina Marriott Larson", "age": 48, "title": "COO & President", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 702244, "exercisedValue": 397610, "unexercisedValue": 5431264}, {"maxAge": 1, "name": "Dr. Blake C. Borgeson Ph.D.", "age": 41, "title": "Co-Founder & Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Secora Ph.D.", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 629782, "exercisedValue": 3620625, "unexercisedValue": 8705478}, {"maxAge": 1, "name": "Dr. David J. Mauro M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 674737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kevin  Leggat", "title": "Vice President of Finance & Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Mabey M.S.", "age": 40, "title": "Chief Technology Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jared  Allenbach", "title": "Senior Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  Hatfield", "title": "Chief Legal Officer & General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Kelly", "title": "Chief Communications Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 7, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.03, "open": 9.1, "dayLow": 8.9731, "dayHigh": 9.31, "regularMarketPreviousClose": 9.03, "regularMarketOpen": 9.1, "regularMarketDayLow": 8.9731, "regularMarketDayHigh": 9.31, "beta": 0.848, "forwardPE": -4.8983955, "volume": 3364080, "regularMarketVolume": 3364080, "averageVolume": 5667957, "averageVolume10days": 6233920, "averageDailyVolume10Day": 6233920, "bid": 9.14, "ask": 9.17, "bidSize": 1000, "askSize": 2200, "marketCap": 2177002240, "fiftyTwoWeekLow": 4.97, "fiftyTwoWeekHigh": 16.745, "priceToSalesTrailing12Months": 47.08559, "fiftyDayAverage": 9.058, "twoHundredDayAverage": 8.917975, "currency": "USD", "enterpriseValue": 1931654016, "floatShares": 191911641, "sharesOutstanding": 230274000, "sharesShort": 40497913, "sharesShortPriorMonth": 39761938, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.17040001, "heldPercentInsiders": 0.051799998, "heldPercentInstitutions": 0.97190005, "shortRatio": 9.27, "shortPercentOfFloat": 0.2569, "bookValue": 1.689, "priceToBook": 5.4233274, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -354112000, "trailingEps": -1.63, "forwardEps": -1.87, "pegRatio": -0.45, "enterpriseToRevenue": 41.779, "enterpriseToEbitda": -5.526, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RXRX", "underlyingSymbol": "RXRX", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1618579800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b61b6c65-adf4-3158-aa09-6b9439d85de8", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.16, "targetHighPrice": 17.0, "targetLowPrice": 10.0, "targetMeanPrice": 13.0, "targetMedianPrice": 12.5, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 6, "totalCash": 296326016, "totalCashPerShare": 1.247, "ebitda": -349544992, "totalDebt": 50974000, "quickRatio": 4.044, "currentRatio": 4.648, "totalRevenue": 46235000, "debtToEquity": 12.707, "revenuePerShare": 0.211, "returnOnAssets": -0.39824, "returnOnEquity": -0.85192, "freeCashflow": -208611744, "operatingCashflow": -316764000, "revenueGrowth": 0.137, "grossMargins": -0.34504002, "operatingMargins": -6.9763703, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-26"}]